Triple-negative breast cancer (TNBC) represents the most aggressive form of breast cancer (BC), being characterized by a high metastatic rate and a poor prognosis due to its tendency to relapse and the lack of targeted therapies. Inhibition of NAD + synthesis, mostly by targeting Nicotinamide Phosphoribosyltransferase in the salvage pathway, showed promise as anticancer therapy, as NAD + is implicated in tumor growth, energy production, motion and invasiveness, immune response, and multi-drug resistance. We investigated the role of Nicotinate Phosphoribosyltransferase (NAPRT), the rate-limiting enzyme for NAD + synthesis starting from nicotinate, in TNBC proliferation, invasiveness, also through the use of a 3D culture model, and in Ca 2+ homeostasis. Our results demonstrated that NAPRT promotes tumor aggression and determines the concomitant increase of the cytosolic Ca 2+ levels and the decrease in state of replenishment of Thapsigargin-sensitive ER Ca 2+ stores. Also, NAPRT overexpression increased the levels of the Ca 2+ -mobilizing messengers cyclic ADPR and Nicotinic Acid Adenine Dinucleotide Phosphate (measurements with a newly developed assay) and the pharmacological CD38 or SARM1 inhibition reverted the NAPRT-induced changes in Ca 2+ homeostasis. Therefore, targeting NAPRT may represent a promising strategy to slow down TNBC growth and progression.
No takes yet. Share an insight, caveat, or question.
Astigiano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: